ESAs Yields Response in VEXAS Syndrome With or Without MDS
In patients with VEXAS Syndrome with or without MDS, ESAs/luspatercept generated positive hematologic improvement-erythroid responses.
Venetoclax Plus Hypomethylating Agents Elicit Encouraging Responses in MDS
Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.
Novel Scoring System May Improve Risk Stratification in MDS Subtype
The IPSS-del(5q) Scoring System shows that factors including male sex, cytopenias, and complex genetic background worsen the prognosis of MDS-del(5q).
Low Dose Deferasirox Yields Promising Transfusion Independence in MDS
For patients with MDS who are relapsed/refractory to erythropoietin stimulating agents, low-dose deferasirox demonstrated promising efficacy and tolerability outcomes.
Genetic Mutations and Disease Progression in MDS Increased by Tobacco Smoking
Smoking may contribute to genetic mutations and disease progression in myelodysplastic syndromes, a recent study found.
